Not Tagged
Not Tagged
['sunitinib', 'pazopanib', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
now at #gu23 (abstract #633), we present on the survival benefit of fda-approved therapies for metastatic renal cell carcinoma from 2005-2022. there were 16 drug (single or combination) approvals for mrcc. most approvals (93.75%) were granted through accelerated approval. 
Physician and researcher with interests in genitourinary cancers and health policy. Tweets are my own views, and are not medical advice.